A systematic review and meta-analysis found that starting urate-lowering therapy (ULT) during a gout flare does not impact the severity, duration, or risk of recurrence over the following month. The study included six randomized controlled trials with a total of 455 participants. Results showed no differences in pain scores, time to resolution of the flare, or risk for flare recurrence when ULT was initiated during a gout flare compared to delayed initiation or placebo. The findings suggest that an individualized approach to patient management is recommended when determining when to start ULT for gout.
Source link
Gout flare severity, recurrence risk not impacted by timing of urate lowering therapy
